NeuroOne Medical Technologies (NASDAQ:NMTC) Upgraded at Wall Street Zen

NeuroOne Medical Technologies (NASDAQ:NMTC) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Separately, Zacks Research raised shares of NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $2.23.

NeuroOne Medical Technologies Stock Down 4.0%

NMTC opened at $0.68 on Friday. NeuroOne Medical Technologies has a 12-month low of $0.40 and a 12-month high of $1.18. The business has a 50 day moving average of $0.81 and a 200-day moving average of $0.80. The stock has a market cap of $34.36 million, a price-to-earnings ratio of -4.00 and a beta of 0.71.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.The business had revenue of $2.89 million for the quarter, compared to analyst estimates of $2.47 million.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Sio Capital Management LLC bought a new position in NeuroOne Medical Technologies during the second quarter worth about $2,390,000. Vanguard Group Inc. grew its position in shares of NeuroOne Medical Technologies by 31.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after purchasing an additional 375,639 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of NeuroOne Medical Technologies by 10.2% during the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after purchasing an additional 70,428 shares during the period. Essex Investment Management Co. LLC acquired a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at approximately $143,000. Finally, Virtu Financial LLC acquired a new stake in shares of NeuroOne Medical Technologies in the third quarter valued at approximately $88,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.